A recent study demonstrated that maternal diet induced obesity contributed to metabolism disorder, hepatic lipotoxicity, and liver steatosis in the offspring, and Bezafibrate, which targets PPAR, had beneficial effects in ameliorating these disorders, predominately through the PPARγ activation and the increased PPARα/PPARγ ratio in the liver [29]. This evidence concerns the gene PPARA and fatty liver disease.